Boston Scientific’s (BSX) “Buy” Rating Reaffirmed at BMO Capital Markets

BMO Capital Markets restated their buy rating on shares of Boston Scientific (NYSE:BSX) in a research report sent to investors on Tuesday. BMO Capital Markets currently has a $32.00 target price on the medical equipment provider’s stock.

BSX has been the subject of a number of other reports. SunTrust Banks set a $34.00 target price on shares of Boston Scientific and gave the stock a buy rating in a report on Tuesday, October 31st. Zacks Investment Research lowered shares of Boston Scientific from a buy rating to a hold rating in a research note on Monday, October 30th. BidaskClub lowered shares of Boston Scientific from a hold rating to a sell rating in a research note on Saturday, August 26th. Needham & Company LLC raised shares of Boston Scientific from a buy rating to a strong-buy rating and raised their price objective for the stock from $25.04 to $32.00 in a research note on Friday, December 8th. Finally, Cowen set a $31.00 price objective on shares of Boston Scientific and gave the stock a buy rating in a research note on Thursday, November 30th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Boston Scientific currently has a consensus rating of Buy and a consensus price target of $31.03.

Shares of Boston Scientific (BSX) opened at $25.78 on Tuesday. The firm has a market cap of $35,181.29, a P/E ratio of 21.00, a P/E/G ratio of 1.98 and a beta of 0.96. Boston Scientific has a 1-year low of $21.29 and a 1-year high of $29.93. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58.

Boston Scientific (NYSE:BSX) last issued its earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.31. The firm had revenue of $2.22 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period last year, the firm posted $0.27 earnings per share. equities research analysts predict that Boston Scientific will post 1.25 EPS for the current fiscal year.

In related news, insider Valley Gold Master Fund L. Sun bought 408,006 shares of the firm’s stock in a transaction on Tuesday, November 28th. The stock was bought at an average price of $0.45 per share, with a total value of $183,602.70. Also, EVP Timothy A. Pratt sold 11,061 shares of Boston Scientific stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $29.24, for a total transaction of $323,423.64. Following the sale, the executive vice president now directly owns 174,681 shares of the company’s stock, valued at approximately $5,107,672.44. The disclosure for this sale can be found here. Insiders have sold a total of 424,698 shares of company stock valued at $12,273,553 in the last three months. Company insiders own 0.74% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Parametric Portfolio Associates LLC raised its holdings in shares of Boston Scientific by 12.0% during the 3rd quarter. Parametric Portfolio Associates LLC now owns 2,947,432 shares of the medical equipment provider’s stock valued at $85,977,000 after purchasing an additional 314,917 shares in the last quarter. Steward Partners Investment Advisory LLC bought a new position in shares of Boston Scientific during the 3rd quarter valued at $139,000. Salem Investment Counselors Inc. raised its holdings in shares of Boston Scientific by 7.6% during the 3rd quarter. Salem Investment Counselors Inc. now owns 125,175 shares of the medical equipment provider’s stock valued at $3,683,000 after purchasing an additional 8,802 shares in the last quarter. Iguana Healthcare Management LLC raised its holdings in shares of Boston Scientific by 127.3% during the 3rd quarter. Iguana Healthcare Management LLC now owns 125,000 shares of the medical equipment provider’s stock valued at $3,646,000 after purchasing an additional 70,000 shares in the last quarter. Finally, Moors & Cabot Inc. raised its holdings in shares of Boston Scientific by 3.7% during the 3rd quarter. Moors & Cabot Inc. now owns 49,975 shares of the medical equipment provider’s stock valued at $1,468,000 after purchasing an additional 1,800 shares in the last quarter. Institutional investors and hedge funds own 90.57% of the company’s stock.

WARNING: This piece was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2017/12/16/boston-scientifics-bsx-buy-rating-reaffirmed-at-bmo-capital-markets.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply